Market access in healthcare is the process of getting a new drug, device, or therapy not just approved by regulators, but actually available and affordable to patients who need it. Regulatory approval is only the starting line. After that comes a separate, often longer series of negotiations involving pricing, reimbursement decisions, and evidence reviews that determine whether patients can actually receive the treatment. A drug can be scientifically proven to work and still sit out of reach if it fails at the market access stage.
Why Approval Alone Isn’t Enough
Most people assume that once a drug gets the green light from the FDA or the European Medicines Agency, it’s available to patients. In reality, regulatory approval and patient access are two distinct hurdles. Regulatory agencies evaluate whether a treatment is safe and effective. Market access decisions, made by a completely different set of organizations, determine whether anyone will pay for it and at what price.
The gap between these two decisions can be significant. Research examining 65 drug-and-indication combinations across cancer treatments in Australia, Canada, and Europe found that in only 50% of cases were there no restrictions beyond the original regulatory label. In another 15% of assessments, access was limited to a smaller subgroup of the patients who were technically eligible based on the approved use. That means roughly one-third of approved cancer therapies faced meaningful restrictions that kept clinically eligible patients from receiving them.
In Europe, once a medicine receives EU-wide marketing authorization, pricing and reimbursement decisions happen separately at the national or regional level. The European Medicines Agency has no role in those decisions. So a treatment approved for all 27 EU member states might be reimbursed in some countries and not others, or reimbursed with different restrictions in each.
The Core Components of Market Access
Market access isn’t a single activity. It’s a framework built on several interlocking pieces, each of which must succeed for patients to ultimately benefit from a new therapy.
- Pricing strategy: Setting a price that reflects the treatment’s clinical value while remaining acceptable to the organizations that will pay for it. Price too high and payers reject it. Price too low and the company can’t sustain the investment required to develop it.
- Health technology assessment (HTA): A formal evaluation of whether a treatment delivers enough benefit relative to its cost. HTA bodies examine clinical evidence, compare the new therapy to existing options, and issue recommendations on whether it should be funded. Effectiveness and cost are important criteria in every country, though cost considerations often vary case by case.
- Reimbursement: The decision by a government health system or private insurer to cover the treatment. This is the step that translates a positive assessment into actual patient access. Without reimbursement, a treatment exists in theory but not in practice for most people.
- Evidence generation: Building the clinical and economic data that supports all of the above. This includes not only the trial data submitted for regulatory approval but also longer-term outcomes data, cost-effectiveness analyses, and real-world evidence gathered after launch.
These components don’t happen sequentially after approval. Modern market access planning starts years earlier, often during Phase II clinical trials, shaping how studies are designed so the resulting data will satisfy not just regulators but also the payers and HTA bodies that come next.
Who Makes the Decisions
Market access involves a broad cast of stakeholders, and their influence varies by country. At the center of most systems is an appraisal committee: a group that reviews the evidence and recommends whether a treatment should be funded. These committees typically include clinicians, health economists, patient representatives, ethicists, academics, and sometimes members of the general public. Their job is to weigh clinical benefit against cost and determine whether a new therapy represents good value for a healthcare system’s limited budget.
Drug manufacturers engage with these bodies at multiple points. They submit applications with supporting evidence, respond to questions during the review, and can appeal unfavorable decisions. Some HTA organizations, like England’s NICE, even offer paid advisory services to help companies understand what evidence will be expected and how to engage patients in the process. If funding is denied for a treatment that addresses a serious condition with no alternatives, additional meetings may be held to resume price negotiations or explore other funding pathways.
Patients are increasingly part of this process too, though their involvement remains uneven. Most patient engagement happens through public consultation periods. Direct collaboration with appraisal committees is less common, and organizations report ongoing challenges with recruiting patient participants and dedicating the time and resources needed for meaningful involvement.
How the US Differs From Europe
The structure of market access looks very different depending on where you are. In most European countries, centralized HTA bodies directly influence which treatments patients can receive. A recommendation from NICE in England or the G-BA in Germany carries real weight because these organizations are tied to the funding mechanisms of national health systems.
The United States has no equivalent centralized gatekeeper. US payers are not bound by the recommendations of any HTA body. Instead, each private insurer and pharmacy benefit manager relies on its own internal committees for coverage decisions. This means coverage can vary between insurers, and a treatment that one plan covers generously might face significant restrictions under another. The result is a more fragmented landscape where market access strategy must be tailored payer by payer rather than directed at a single national body.
A major recent shift in the US is Medicare’s authority to directly negotiate prices for certain drugs, which changes the financial calculus for manufacturers. Post-approval research to support expanded uses now faces a compressed timeline for return on investment, since Medicare negotiation timelines begin from the date of initial FDA approval.
The Investment Behind It
To understand why market access matters so much, consider the financial arc of a new drug. Development typically spans 10 to 12 years of negative cash flow, covering preclinical research, animal testing, and up to three phases of clinical trials. Revenue only begins after regulatory approval, and even then, the costs don’t stop. Manufacturers still spend on obtaining reimbursement in each market, generating additional evidence, manufacturing, and marketing.
A drug that wins regulatory approval but fails to secure favorable pricing or reimbursement in major markets may never recoup its development costs. This is why pharmaceutical companies now invest heavily in market access teams and begin planning their strategy years before a product reaches regulators.
Value-Based Agreements and New Models
The traditional model of fixed pricing is gradually giving way to value-based arrangements, where payment is tied more closely to outcomes. Over 60% of healthcare organizations have increased their participation in value-based care programs, and 30% report that at least a quarter of their revenue is already tied to these contracts. About 13% have crossed the 50% revenue threshold, and 64% of organizations expect the shift toward value-based care to accelerate in 2025.
For market access, this trend means that demonstrating real-world outcomes is becoming as important as demonstrating efficacy in controlled trials. Payers increasingly want to see evidence that a treatment works in everyday clinical practice, not just in the carefully selected populations of clinical studies. Some agreements now link the price a payer pays to measurable patient outcomes, sharing the financial risk between manufacturer and health system.
Recent Policy Changes in Europe
One of the most significant recent developments is the EU’s move toward joint clinical assessments. Starting January 12, 2025, new cancer medicines and advanced therapy products are subject to a shared clinical evaluation process across EU member states. When a manufacturer submits a marketing authorization application to the European Medicines Agency, it must simultaneously submit clinical documentation to a centralized HTA secretariat.
This doesn’t eliminate country-level pricing and reimbursement decisions, but it standardizes the clinical evaluation that feeds into those decisions. Previously, each country conducted its own clinical review, leading to duplication of effort and inconsistent conclusions. The new system assigns an assessor and co-assessor to each product, creating a single clinical assessment that all member states can reference when making their own funding choices.
Patient Assistance as a Stopgap
When market access efforts fall short or leave coverage gaps, patient assistance programs can serve as a partial safety net. Pharmaceutical manufacturers sponsor these programs to provide financial help or free medication to lower-income patients. In the US, these programs can supplement Medicare Part D coverage, though with an important limitation: the assistance doesn’t count toward a patient’s true out-of-pocket costs, which means it doesn’t help them reach the catastrophic coverage threshold faster.
These programs are not a substitute for broad reimbursement. They typically reach a fraction of eligible patients and require individual applications. But they represent one more layer in the complex system that determines whether a treatment that exists on paper actually reaches the person who needs it.